A seasoned executive with extensive experience in the operations of publicly listed companies and deep cross-sector connections within the financial industry. He has demonstrated long-term commitment to the biopharmaceutical and biotech sectors, with expertise spanning cross-border equity investments, project financing, mergers and acquisitions (M&A), and strategic government engagement.